文献速递其他结缔组织病血管炎

非TNF靶向生物制剂治疗白塞病:国际AIDA注册登记的真实世界数据

The use of non-TNF targeted biologics in Behçet's disease: real-life data from the International AIDA Network Behçet's Disease Registry.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究基于国际AIDA网络白塞病注册登记数据,纳入65例曾使用非TNF靶向生物制剂的白塞病患者,评估阿那白滞素、卡那单抗、托珠单抗、司库奇尤单抗、依奇珠单抗、乌司奴单抗和利妥昔单抗的真实使用、疗效与安全性。结果显示IL-1、IL-6、IL-17及IL-12/23通路靶向药物可为TNF-α抑制剂无效者提供替代选择,但疗效因表型而异,需个体化决策。

要点

  • 阿那白滞素最常用(n=31),对黏膜皮肤、肌肉骨骼和眼部受累部分或完全缓解率分别为34.7%、73.3%和77.7%。
  • 托珠单抗对眼部和神经系统受累有效(6例中5例完全缓解),但40%黏膜皮肤表现恶化或无应答。
  • IL-17抑制剂对黏膜皮肤-关节表型有效,尤其合并中轴型脊柱关节炎者;各治疗组未报告新的重大安全性问题。

核心结论

  • 靶向IL-1、IL-6、IL-17及IL-12/23通路的生物制剂可为TNF-α抑制剂无效的白塞病患者提供治疗替代选择。
  • 不同表型的疗效存在差异,强调需个体化治疗决策。

研究设计与样本

  • 研究基于国际自身炎症性疾病联盟(AIDA)网络白塞病注册登记数据,纳入随访期间曾接受任何非TNF-α抑制剂生物制剂的患者。
  • 共纳入65例患者(36例女性/29例男性),平均年龄45.8±13.3岁,收集3、6、12个月随访的临床人口学特征、既往治疗及治疗反应。

主要发现

  • 阿那白滞素最常用(n=31),黏膜皮肤、肌肉骨骼和眼部受累的部分或完全缓解率分别为34.7%、73.3%和77.7%。
  • 卡那单抗(n=11)对黏膜皮肤、肌肉骨骼和眼部受累有效,包括部分既往对阿那白滞素无应答者。
  • 托珠单抗(n=15)对眼部和神经系统受累显示良好结局(6例中5例完全缓解),但40%黏膜皮肤表现恶化或无应答。
  • 司库奇尤单抗和依奇珠单抗对黏膜皮肤-关节表型有效,尤其合并中轴型脊柱关节炎者;乌司奴单抗(n=3)和利妥昔单抗(n=5)在部分难治性病例中显示临床改善。
  • 各治疗组未报告新的重大安全性问题。

关键数值与推荐

  • 阿那白滞素治疗患者中黏膜皮肤受累部分或完全缓解率为34.7%,肌肉骨骼受累为73.3%,眼部受累为77.7%。
  • 托珠单抗治疗患者中眼部和神经系统受累6例中5例完全缓解,黏膜皮肤表现40%恶化或无应答。
  • 卡那单抗(n=11)对黏膜皮肤、肌肉骨骼和眼部受累有效;乌司奴单抗(n=3)和利妥昔单抗(n=5)在部分难治性病例中显示临床改善。

临床怎么用

  • 对TNF-α抑制剂无效或不耐受的白塞病患者,可考虑靶向IL-1、IL-6、IL-17或IL-12/23通路的生物制剂。
  • 治疗选择应结合受累表型:眼部/神经系统受累可考虑托珠单抗,黏膜皮肤-关节表型尤其合并中轴型脊柱关节炎者可考虑IL-17抑制剂。

局限性

  • 研究为注册登记的真实世界数据,样本量较小(65例),部分药物亚组例数很少(如乌司奴单抗n=3、利妥昔单抗n=5)。
  • 原文未报告对照设计、盲法或统计比较,疗效数据为描述性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Refractory manifestations of Behçet's disease (BD) are commonly treated with TNF-α inhibitors; however, a subset of patients do not respond or are intolerant, prompting the need for alternative therapies. This study aimed to assess the real-life use, efficacy, and safety of non-TNF targeted biologic agents in BD. METHODS: Data were retrieved from the International AutoInflammatory Disease Alliance (AIDA) Network Registry for BD. Patients who received any biologic agent other than TNF-α inhibitors at any point during follow-up were included in the study. Clinical and demographic characteristics, prior treatments, and treatment responses at the 3-, 6- and 12-month follow-ups were collected. RESULTS: In total, 65 patients (36 female/29 male) with a mean age of 45.8 ± 13.3 years were included in the sample population for this study. Anakinra was the most frequently used agent (n = 31), with 34.7% of patients with mucocutaneous, 73.3% with musculoskeletal, and 77.7% with ocular involvement showing a partial or complete response. Canakinumab (n = 11) was effective in mucocutaneous, musculoskeletal and ocular involvement, including in some patients previously unresponsive to anakinra. Tocilizumab (n = 15) showed favourable outcomes in ocular and neurological involvement (a complete response in 5 of 6 patients), while 40% experienced worsening or no response in mucocutaneous manifestations. Secukinumab and ixekizumab were effective in patients with mucocutaneous-articular phenotypes, especially those with axial SpA. Ustekinumab (n = 3) and rituximab (n = 5) also demonstrated clinical improvement in selected refractory cases. No new major safety concerns were reported across the treatment groups. CONCLUSION: Biologics targeting IL-1, IL-6, IL-17 and the IL-12/23 pathways may offer therapeutic alternatives in BD patients unresponsive to TNF-α inhibitors. The treatment efficacy varied across phenotypes, highlighting the need for individualized treatment decisions.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sevik G, Lopalco G, Iannone F, et al. The use of non-TNF targeted biologics in Behçet's disease: real-life data from the International AIDA Network Behçet's Disease Registry. Rheumatology (Oxford). 2026. PMID: 41703603. doi:10.1093/rheumatology/keag086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。